Southport Weight Loss

Southport Weight Loss operates as a physician-supervised metabolic clinic in Southport, Indiana, focusing exclusively on prescription-based weight management for adults with obesity and metabolic dysfunction. Dr. Sarah Mitchell, the clinic's medical director, holds board certification in family medicine and has completed advanced training in obesity medicine through the American Board of Obesity Medicine. The practice serves patients throughout Marion County and the greater Indianapolis metropolitan area, with a patient population that includes individuals managing type 2 diabetes, prediabetes, hypertension, and dyslipidemia alongside excess weight.

The clinic's treatment protocols center on GLP-1 receptor agonist medications, specifically semaglutide and tirzepatide, which are FDA-approved for chronic weight management in adults with a body mass index of 30 or greater, or 27 or greater with at least one weight-related comorbidity. Dr. Mitchell prescribes these medications following comprehensive metabolic assessment that includes fasting glucose, hemoglobin A1c, lipid panel, thyroid function tests, and liver enzyme evaluation. Patients receive individualized dosing schedules that follow manufacturer titration protocols, with weekly subcutaneous injections administered at home after in-office training. The clinic also offers liraglutide for patients who may benefit from daily dosing or have insurance coverage limitations for newer agents. Each medication plan includes specific dietary guidance aligned with the mechanism of action of GLP-1 agonists, which slow gastric emptying and reduce appetite through central nervous system pathways.

Dr. Mitchell conducts initial consultations that last approximately 45 minutes and include review of prior weight loss attempts, current medications, family history of obesity and metabolic disease, and discussion of realistic weight loss expectations based on clinical trial data. She emphasizes that GLP-1 medications typically produce 15-20% total body weight reduction over 12-18 months when combined with lifestyle modification, and that treatment represents long-term metabolic management rather than a temporary intervention. The clinic does not employ nurse practitioners or physician assistants; all medical decision-making and prescription management occurs directly with Dr. Mitchell. Follow-up appointments occur every four weeks during the titration phase and every 8-12 weeks during maintenance, with each visit including weight measurement, blood pressure assessment, review of side effects, and adjustment of dosing as clinically indicated.

Patients at Southport Weight Loss receive structured monitoring for common GLP-1 side effects including nausea, constipation, and gastrointestinal discomfort, with specific protocols for managing these symptoms through dietary modification, hydration strategies, and temporary dose adjustment when necessary. The clinic maintains a patient portal for secure messaging regarding side effects or questions between scheduled appointments. Dr. Mitchell also monitors for rare but serious adverse effects including pancreatitis, gallbladder disease, and diabetic retinopathy progression in susceptible individuals. Laboratory monitoring occurs at baseline, three months, six months, and annually thereafter, with additional testing as clinically warranted based on individual patient factors. The practice coordinates care with patients' primary care physicians and endocrinologists, providing detailed treatment summaries and medication lists to ensure continuity across providers.

Southport Weight Loss does not currently offer telehealth services, requiring all patients to attend in-person appointments at the Southport clinic location for medication prescribing and monitoring in accordance with Indiana medical board regulations. The clinic accepts most major insurance plans for office visits and metabolic testing, though patients should verify coverage for GLP-1 medications directly with their insurance carrier, as formulary coverage varies significantly between plans. For patients without insurance coverage for these medications, the clinic provides information about manufacturer savings programs and alternative payment options. Dr. Mitchell does not prescribe compounded semaglutide or tirzepatide, utilizing only FDA-approved branded formulations to ensure consistent dosing, sterility, and regulatory oversight. The practice maintains evening appointment availability on Tuesdays and Thursdays to accommodate working patients throughout the Indianapolis area.